Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 603 |
Ending reported balance
After 2026-09-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-02 · Exercise / conversion · Acquired 400 · Balance 1,003 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. Row 2 · 2026-09-02 · Sale · Disposed 400 · Balance 603 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $719.37 · Expires 2035-01-02 | Direct | 1,158 |
Reported balance
After 2026-09-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-02 · Exercise / conversion · Disposed 400 · Balance 1,158 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. F2: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026.
F2: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 20:47 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $719.37 | $0.00 |
DisclosureSEC source: 0001992352-26-000007 · edgardoc.xml · derivative · entry 3 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,158 Underlying: Common Stock · 400 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. F2 · derivative.exercise_date: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 20:47 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $850.00 | $340,000.00 |
DisclosureSEC source: 0001992352-26-000007 · edgardoc.xml · nonDerivative · entry 2 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 603 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 20:47 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 400 | $719.37 | $287,748.00 |
DisclosureSEC source: 0001992352-26-000007 · edgardoc.xml · nonDerivative · entry 1 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $719.37 | $0.00 |
DisclosureSEC source: 0001992352-26-000005 · edgardoc.xml · derivative · entry 3 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 400 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. F2 · derivative.exercise_date: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $800.00 | $320,000.00 |
DisclosureSEC source: 0001992352-26-000005 · edgardoc.xml · nonDerivative · entry 2 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 603 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 400 | $719.37 | $287,748.00 |
DisclosureSEC source: 0001992352-26-000005 · edgardoc.xml · nonDerivative · entry 1 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,962 | $0.00 Strike: $772.76 | $0.00 |
DisclosureSEC source: 0001992352-26-000003 · edgardoc.xml · derivative · entry 2 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,962 Underlying: Common Stock · 1,962 shares Expires 2036-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001992352-26-000003 · edgardoc.xml · nonDerivative · entry 1 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 603 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,958 | $0.00 Strike: $719.37 | $0.00 |
DisclosureSEC source: 0001968202-25-000005 · edgardoc.xml · derivative · entry 2 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,958 Underlying: Common Stock · 1,958 shares Expires 2035-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 166 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-25-000005 · edgardoc.xml · nonDerivative · entry 1 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 508 | $0.00 Strike: $888.34 | $0.00 |
DisclosureSEC source: 0001883850-24-000002 · edgardoc.xml · derivative · entry 2 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 508 Underlying: Common Stock · 508 shares Expires 2034-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 42 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000002 · edgardoc.xml · nonDerivative · entry 1 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,739 | $0.00 Strike: $833.23 | $0.00 |
DisclosureSEC source: 0001104659-23-099988 · tm2325700-3_4seq1.xml · derivative · entry 2 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,739 Underlying: Common Stock · 2,739 shares Expires 2033-09-08 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 240 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-099988 · tm2325700-3_4seq1.xml · nonDerivative · entry 1 Guarini Kathryn · CIK 0001992352 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.